



**University of
Zurich^{UZH}**

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2013

Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach

Riemenschneider, M J ; Louis, D N ; Weller, M ; Hau, P

Abstract: Individualized therapies are popular current concepts in oncology and first steps towards stratified medicine have now been taken in neurooncology through implementation of stratified therapeutic approaches. Knowledge about the molecular basis of brain tumors has expanded greatly in recent years and a few molecular alterations are studied routinely because of their clinical relevance. However, no single targeted agent has yet been fully approved for the treatment of glial brain tumors. In this review, we argue that multidisciplinary and integrated approaches are essential for translational research and the development of new treatments for patients with malignant gliomas, and we present a conceptual framework in which to place the components of such an interdisciplinary approach. We believe that this ambitious goal can be best realized through strong cooperation of brain tumor centers with local hospitals and physicians; such an approach enables close dialogue between expert subspecialty clinicians and local therapists to consider all aspects of this increasingly complex set of diseases.

DOI: <https://doi.org/10.1007/s00401-013-1127-4>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-79908>

Journal Article

Accepted Version

Originally published at:

Riemenschneider, M J; Louis, D N; Weller, M; Hau, P (2013). Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. *Acta Neuropathologica*, 126(1):21-37.

DOI: <https://doi.org/10.1007/s00401-013-1127-4>

Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach

Markus J. Riemenschneider^{1,5}, David N. Louis², Michael Weller³ and Peter Hau^{4,5}

¹Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany; ²Pathology Service and Cancer Center, Massachusetts General Hospital and Department of Pathology, Harvard Medical School, Boston, MA, USA; ³Department of Neurology, University Hospital Zurich, Zurich, Switzerland; ⁴Department of Neurology, University of Regensburg, and ⁵Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Regensburg, Germany.

Running title: Molecular based diagnostics and therapy in neurooncology

Key words: glioblastoma, anaplastic glioma, molecular diagnostics, *BRAF* duplication, *IDH1* mutation, *MGMT* promoter methylation, 1p/19q deletion

Corresponding author:

Markus J. Riemenschneider, M.D., Department of Neuropathology, Regensburg University Hospital, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany, Phone: +49-941-9445150, Fax: +49-941-9445152, E-mail: Markus.Riemenschneider@ukr.de

Abstract

Individualized therapies are popular current concepts in oncology and first steps towards stratified medicine have now been taken in neurooncology through implementation of stratified therapeutic approaches. Knowledge about the molecular basis of brain tumors has expanded greatly in recent years and a few molecular alterations are studied routinely because of their clinical relevance. However, no single targeted agent has yet been fully approved for the treatment of glial brain tumors. In this review, we argue that multidisciplinary and integrated approaches are essential for translational research and the development of new treatments for patients with malignant gliomas, and we present a conceptual framework in which to place the components of such an interdisciplinary approach. We believe that this ambitious goal can be best realized through strong cooperation of brain tumor centers with local hospitals and physicians; such an approach enables close dialogue between expert subspecialty clinicians and local therapists to consider all aspects of this increasingly complex set of diseases.

1 Introduction

2
3 Advances in the understanding of tumor biology and the availability of more sophisticated
4 technical tools for molecular genetic analyses in recent years has led to an exponential
5 increase in the knowledge of genetic alterations linked to gliomagenesis [117, 118]. While
6 these findings have widened our understanding of the underlying biology of the disease, they
7 have also increased our awareness of its complexity. For example, intertumoral and
8 intratumoral heterogeneity may influence outcome and treatment response; the vascular niche,
9 the (hypoxic) stem cell niche or infiltrating glioma cells (to name but a few) all have their
10 own molecular characteristics [76, 116]; and molecular changes occur on multiple regulatory
11 levels (genomic, transcriptional, epigenetic) and are interconnected, such as miRNAs may
12 control sophisticated signaling networks [83, 85, 122]. Taken together, these different facets
13 of the disease have an enormous potential to influence diagnostic decisions and to stimulate
14 the development of novel therapies.

15
16 At the same time, the molecular changes that have been translated into a clinically meaningful
17 context are not many and no targeted agent has yet been fully approved for the treatment of
18 gliomas. A few molecular alterations such as *MGMT* methylation, deletions on chromosome
19 arms 1p/19q and *IDH1/2* mutations have been successfully linked to predictive and/or
20 prognostic information [114, 115]. However, although frequently evaluated, their use for
21 clinical decision-making is not yet widespread in the general community [56]. In addition,
22 novel genetically defined subgroups within histologically homogenous tumor entities and
23 global molecular signatures with prognostically relevant content have been identified [120].
24 Further, we are on the verge of understanding the molecular correlates of chemotherapy
25 resistance. These are first steps emphasizing the transfer of basic research insights into
26 clinically relevant applications. Finally, the interconnection of tissue-based information with
27 data from imaging methods such as magnetic resonance techniques and positron emission
28 tomography plays increasing roles in diagnostics and therapeutics [35]. Here, all types of
29 information converge to establish an optimized treatment strategy.

30
31 With a multitude of molecular alterations now known through high-throughput profiling
32 studies [22], one of the major future challenges will be the determination of how those
33 changes might be exploited to our patients' benefit. While we are far from providing final
34 answers to this important challenge, we here review approaches that connect molecular with

1 histopathological and clinical as well as imaging information. We further believe that such
2 approaches can be best realized in an environment where clinicians and basic scientists work
3 closely together to illuminate the many aspects of this increasingly complex disease and
4 where they connect to local hospitals and physicians to bring optimal treatment to patients. As
5 such we argue that current optimum neuro-oncology treatment and research must be
6 multidisciplinary and interdisciplinary. In the following commentary, we provide a series of
7 arguments and a conceptual framework in support of this statement (Fig. 1).

11 **Argument #1: Diagnosis is necessarily complex and requires expert neuropathologists**

13 ***#1a: Histology and molecular pathology are increasingly interconnected***

14 Since its first edition in 1979, the WHO classification of tumors of the central nervous system
15 has been developed periodically by correlating histopathological findings with clinical
16 information, primarily survival data. To date, the WHO brain tumor classification (most
17 recently updated in 2007) is still based on histological and immunohistochemical findings
18 [78]. However, given the emerging knowledge of the molecular basis of brain tumors,
19 molecular analyses will likely be increasingly incorporated in future revisions of the
20 classification [77]. A few examples in this direction are as follows (also compare Table 1):

- 22 • ***Molecular subtypes of glioblastomas***

23 Histologically defined glioblastoma represents a molecularly diverse set of entities. For
24 example primary (de novo) and secondary (derived from a lower-grade precursor
25 lesion) glioblastoma have long been distinguished from one another [68, 93]. While
26 histologically indistinguishable, these tumors exhibit divergent molecular profiles [74,
27 93, 114]. Data from large-scale profiling approaches (for details see below) identified
28 even higher numbers of molecularly defined glioblastoma subgroups with clinical
29 relevance [99, 140]. For molecular-driven therapies this additional information would
30 have to be incorporated into the overall tissue diagnosis and passed from the
31 neuropathologist to the clinician; to do so in many instances, particularly in the setting
32 of complex diagnostic tests, requires subspecialized expertise.

1 • *Molecular differential diagnoses of astrocytic gliomas*

2 Molecular genetics may be beneficial in stratifying astrocytomas with ambiguous
3 histological features into groups that are more likely to behave similarly in response to
4 treatment. One example in this respect would be the case of high-grade glial neoplasms
5 that appear highly pleomorphic but in which histological criteria for the diagnosis of
6 glioblastoma are not completely fulfilled and uncertainty remains whether this may be
7 merely due to incomplete sampling. In such cases, the presence of a mutant *IDH* might
8 raise caution for the diagnosis of a WHO grade IV lesion, while the *IDH* wildtype
9 situation may support the possibility that the tumor is likely to behave in an
10 unfavorable, glioblastoma-like fashion [4, 47, 59]. As *IDH* mutations are tumor-specific
11 alterations that do not occur in non-neoplastic cell populations, they may also aid in the
12 sometimes subtle differential diagnosis between reactive astrogliosis or the infiltrative
13 rim of a low-grade glioma containing only isolated invading tumor cells [21, 121].
14 Other molecular alterations may support the sometimes difficult differential diagnosis
15 between infiltrating astrocytomas and astrocytic tumors with a more circumscribed
16 growth pattern [78, 119]. As such, *BRAF* gene alterations (and in particular a *BRAF*-
17 *KIAA1549* fusion gene) might help to differentiate pilocytic astrocytomas from
18 diffusely infiltrating low-grade astrocytomas (the latter in turn show common *IDH* gene
19 mutations) [5, 64, 65]. *BRAF V600E* mutations may also provide support for the
20 diagnosis of an (anaplastic) pleomorphic xanthoastrocytoma over that of a glioblastoma
21 [125, 143].

22
23 • *Molecular diagnostics of oligodendroglial neoplasms*

24 Because oligodendroglial tumors follow a better clinical course and because recent data
25 has shown that 1p/19q-codeleted oligodendroglial tumors should be treated with
26 combined radiochemotherapy, their precise histological identification is of major
27 clinical importance [20, 112, 138]. However, the histological features of
28 oligodendroglial differentiation are prone to marked interobserver variability [71, 135].
29 In such cases, the integration of histological and molecular information becomes
30 important. While it is still a matter of debate if the presence of 1p/19q deletions should
31 define oligodendroglioma, these prognostically favorable molecular alterations are very
32 common in oligodendroglial tumors (up to 80% of oligodendrogliomas and 30-50% of
33 oligoastrocytomas) [18, 19, 20, 136, 138, 148]. Thus, in cases with questionable
34 oligodendroglial histology, 1p/19q testing can help to identify those patients that follow

1 a better clinical course. In terms of therapies for oligoastrocytoma, this combination of
2 histological and molecular information is also important because these tumors do not
3 form a homogeneous group of neoplasms and histology alone does not sufficiently
4 reveal their nature. Only molecular analysis can segregate lesions with the molecular
5 characteristics of an oligodendroglioma (1p/19q codeletion) from those that more
6 resemble a diffusely infiltrating astrocytic neoplasm (*TP53* mutation, 17p loss,
7 chromosome 7 gain) [81, 88].

8
9 These three examples emphasize that a combination of histology, immunohistochemistry and
10 molecular genetics is required for diagnostic approaches. The combination is more than the
11 mere synopsis of the information obtained from the different investigative levels. Accurate
12 brain tumor classification has to weigh histological and molecular information carefully in
13 light of the therapeutic options available. In many instances, brain tumor diagnostics is not
14 straightforward and requires a high degree of expertise and knowledge about the clinical
15 consequences of a specific differential diagnosis.

16
17 The diagnosis of rare tumor entities also carries challenges. Tumors such as angiocentric
18 glioma, papillary tumors of the pineal region, papillary glioneuronal tumor and rosette-
19 forming glioneuronal tumor of the fourth ventricle have only recently been added to the WHO
20 classification [78]. Most of these tumors are rare and awareness of their existence and
21 differential diagnosis is more likely in neuropathological institutions where such tumors are
22 seen in greater numbers. Once identified, the lack of extensive published experience treating
23 such tumors means that the clinical implications of such diagnoses have to be individualized.
24 Thus, although the details of these rare entities is beyond the scope of this review, their rarity
25 makes them as important as common entities in terms of this conceptual framework of
26 interdisciplinary clinical approaches.

27 28 29 ***#1b: Proper molecular diagnostics requires dual molecular and histopathological expertise***

30 Tissue expertise is a required starting point for state-of-the-art molecular diagnostics. The
31 proper work-up of tissue specimens can be complex and requires the expertise of a
32 neuropathologist. For example, because most molecular assays are tumor-lysate based
33 approaches, histopathological characterization to identify representative tumor tissue is
34 essential prior to homogenization. In addition, tumor cell content should be carefully

1 controlled for since some assays (such as *MGMT* methylation testing, which requires cut-off
2 values and reports percentages) depend on a sufficient tumor cell content within the sample
3 [115]. In this context, it is important to point out that nearly all molecular tests have not yet
4 been validated independently, leading to discrepancies between laboratories.

5 For example, several methylation assays have been described for *MGMT* promoter
6 methylation testing. In addition to the methylation-specific PCR assay [52], combined
7 bisulfite restriction analysis, methylation specific sequencing and pyrosequencing as well
8 restriction enzyme-based approaches (that do not require bisulfite conversion, e.g. methyl-
9 QESD [10]) are in use. For the assays, primers are not standardized between laboratories so
10 that different regions of the gene promotor and a different number of CG sites are being
11 assessed. In this regard, it is unclear which methylation site corresponds best to clinical
12 response [27]. Such pitfalls handicap the comparability of testing results between individual
13 laboratories and make definition of clear cut-off levels questionable [115]. For these reasons,
14 the establishment of a consensus testing method that enables interlaboratory testing would be
15 desirable. New directions could involve combined assessment of gene methylation with
16 protein expression [72, 146]. Such consensus would require inter-institutional agreements,
17 perhaps through the involvement of national and international trial organizations.

18 Similar quality and comparability aspects have to be taken into consideration for assays of 1p
19 and 19q deletions where PCR-based and FISH methods coexist and deletions of specific
20 regions may bear an inverse prognostic meaning [41, 139]. All these natural limitations of the
21 methods have to be kept in mind and, in combination with the histological findings, have to
22 be adequately communicated to the clinician.

23
24
25 ***#1c: Correct diagnosis and tissue processing is the basis for interpretation of research***
26 ***results.***

27 Another important aspect that requires the input of neuropathologists is brain tumor banking.
28 Tumor banking stimulates basic, translational and clinical research aspects in many ways. The
29 collection of prospective cohorts of clinically well-annotated tumor samples supplies a unique
30 resource for basic researchers and clinicians by combining molecular and histopathological
31 with clinical and prognostic information [54, 139]. As a consequence, tissue banks in brain
32 tumor centers are a common resource usually governed by a steering board that involves all
33 disciplines (e.g., neurosurgery, neuropathology, neurology, medical oncology etc.) and
34 decides together on the use of the tissue specimens. A critical step is the proper processing

1 and characterization (e.g., with respect to representativeness and tumor cell content) of
2 surgical tissue specimens prior to banking, which requires expert neuropathological input,
3 particularly from neuropathologists interested in research applications. If research-orientated
4 neuro-oncologists and neurosurgeons then complement clinical information and other
5 additional features (such as patient blood samples), tissue banks become a valuable resource.
6 These resources become potentially yet more valuable if materials and information can be
7 shared in inter-institutional ways, for example to support large trials or large genomic studies.
8 Thus, tumor banks by linking clinical and basic research are an integral part of our
9 conceptional framework and foster innovative treatment approaches (Fig. 1).

13 **Argument #2: Clinical care is necessarily complex and needs expert neurooncologists**

15 ***#2a: Molecular markers increasingly influence therapy decisions***

16 In addition to aiding in diagnosis and classification, molecular markers are now also affecting
17 therapeutic decisions. The prognostic or therapy-predictive role of these markers has been
18 partly clarified within clinical trials. To date, a number of adequately powered phase III- or
19 randomized phase II-clinical trials have been performed or are enrolling. These trials may
20 change the standards for the treatment of high-grade gliomas on basis of molecular
21 evaluations (Table 2). Therefore, molecular markers, particularly in high-grade tumors, will
22 gain an increasing role for therapy stratification, make therapeutic decisions more individual
23 and thus necessitate a close dialogue between clinicians and neuropathologists. This is not
24 only true for medical neurooncologists, but also for neurosurgeons, radiotherapists and
25 diagnostic disciplines as neuroradiology.

26 In the following we provide examples on how molecular information supports current
27 therapeutic decisions in glioblastomas and anaplastic gliomas:

- 29 • ***Clinical impact of molecular markers in glioblastomas***

30 The EORTC 26981/22981 NCI-C3.0 trial demonstrated the relevance of *MGMT*
31 promoter methylation in glioblastomas by comparing treatment with temozolomide
32 radio-chemotherapy with radiotherapy only [52, 131]. In this trial, methylation was
33 predictive for benefit from chemo- and radiotherapy, a result that was later verified in
34 the phase III RTOG 0525 trial [1]. Results from the EORTC 26891 combined treatment

arm are often used as standard arm in trial design, and still, there has been no fully published trial that shows better results. RTOG 0525 failed to show that an intense regimen of temozolomide is more effective than the standard regimen either in patients with glioblastoma with a methylated or unmethylated *MGMT* promoter [1]. However, as there is no approved alternative to radio-chemotherapy with temozolomide at this time, the predictive value of the *MGMT* promoter methylation does not lead to a stratified treatment of patients with glioblastoma. This is different in elderly patients with glioblastoma above an age of 65: efficacy of temozolomide as a monotherapy in older patients was verified in the Nordic trial [82] and the german randomised phase 3 NOA-08 trial; as shown by NOA-08, dose-dense temozolomide and radiotherapy in a conventional fractionation scheme are generally equally effective [149]. However, patients with *MGMT* promoter methylation have an increased overall survival under temozolomide monotherapy. Therefore, these patients should be treated with chemotherapy, whereas patients without *MGMT* promoter methylation or with an unknown *MGMT* status should be treated with radiotherapy. Finally, data that bevacizumab increases PFS from around 6 to 10 months [26] and possible approval of bevacizumab may lead to a shift in the first-line treatment of glioblastomas, leading to bevacizumab treatment in patients with an unmethylated *MGMT* promoter (see #2b, below).

- *Clinical impact of molecular markers in anaplastic gliomas*

In the german NOA-04 trial for anaplastic astrocytomas and anaplastic oligodendroglial tumors, hypermethylation of the *MGMT* promoter, mutation of *IDH1* and oligodendroglial histology were verified as favorable prognostic markers [148]. However, *MGMT* promoter methylation was not predictive for a benefit from chemotherapy. Other publications substantiate the prognostic value of molecular markers in grade III gliomas [137]. In addition, data from two studies on WHO grade III oligodendroglial tumors [20, 138] recently showed that the overall survival of patients with a combined loss of 1p and 19q doubles from approximately 7 to about 14 years if combined treatment with radiotherapy and chemotherapy with procarbazine, CCNU and vincristine (PCV) is used. Even if these data were evaluated retrospectively, they appear so convincing that a paradigmatic change in the treatment of these patients may result; in contrast, patients without 1p/19q loss will most likely be treated with radiotherapy, temozolomide or PCV as a monotherapy.

1 Most of the classical molecular markers have not been prospectively verified in independent
2 trials. In the EORTC 26981/22981 NCI-C3.0 trial, for example, *MGMT* promoter methylation
3 was evaluated post hoc in a subset of 206 of 573 treated patients. The evaluation of fewer than
4 half of the specimens, with the rest of specimens not being available or investigable, may
5 have introduced a statistical bias. Even in later trials with a prospective evaluation of *MGMT*
6 methylation, the rate of evaluated specimen has been in the range of 50-60% [1, 148]. Also,
7 the situations discussed above do not offer a stratified therapeutic approach for all patients
8 with high-grade gliomas, with the situation being even less clear in WHO grade II glioma
9 patients.

10
11 In such instances, crosstalk between tissue and imaging diagnostic disciplines also comes into
12 play and is essential to guide neurosurgery, radiotherapy and treatment response assessment.
13 Therapeutic disciplines increasingly rely on functional and metabolic imaging to guide
14 diagnostics and treatment [2]. For example, neurosurgeons use functional and biological
15 imaging to increase the extent of resection or to guide biopsy of the anaplastic focus of diffuse
16 tumors [40, 96, 145]. However, diagnosis and evaluation of response phenomena such as
17 pseudoprogression and pseudoresponse cannot be solely based on imaging methods, such as
18 MRI and PET [35, 86, 151], as the rate of false positive or negative imaging results is still
19 considerably high. Radiotherapists increasingly plan treatment along the biological tumor
20 volume that is evaluated by positron emission tomography [100, 144], and a value for
21 magnetic resonance spectroscopy has been suggested [39]. In this situation, correlation of the
22 biological tumor volume to histopathological and molecular features will be helpful to verify
23 this approach.

24
25 No single reliable tumor marker has yet been detected for gliomas and serum markers for
26 glioma diagnosis are not available at the present time. Nonetheless, in regard to a potential
27 serum markers for monitoring tumor load or tumor progression, small molecules such as
28 miRNAs might bear promising diagnostic perspectives [57]. Thus, additional controlled
29 studies involving proper histological and molecular work-up and development of novel
30 imaging and serum markers are needed.

31
32 Regardless of the modalities involved, the number of different technologies and the nuances
33 inherent in understanding the evidence levels offered by such approaches, it is clear that

1 treatment decisions for such patients are best discussed in multidisciplinary tumor boards that
2 include experts well aware of the strengths and weaknesses of all of these technologies.

3 4 5 ***#2b: Targeted agents provide therapeutic options beyond standard alkylating chemotherapy***

6 The current goal of many areas of oncology is the development of innovative targeted
7 therapies. Achieving effective targeted approaches will require close interaction between
8 basic scientists and clinicians, as well as a developmental pipeline from basic to translational
9 to clinical research. Most of these approaches are still at an experimental stage and most are
10 therefore introduced later in this review (see #4a below).

11
12 The currently most advanced example of a therapeutic strategy beyond standard alkylating
13 agents is the selective blockade of pro-angiogenic pathways with the humanized monoclonal
14 antibody bevacizumab [62, 101]. By binding the VEGF-A ligand, bevacizumab inhibits the
15 receptor-ligand interaction [66, 129]. Bevacizumab has been used as a monotherapy or in
16 combination with chemotherapeutic agents as irinotecan or temozolomide. In the first phase II
17 trials in relapse of high-grade gliomas, high response rates of up to 63%, a significant increase
18 of progression free survival (PFS) at 6 months (38%), and a small increase of overall survival
19 have been shown in comparison to historical data [142] - observations that however could not
20 be fully substantiated in subsequent trials. In most trials, response rates of about 30% have
21 been reported. Bevacizumab has been preliminarily approved by the FDA for the treatment of
22 relapsing or progressive high-grade gliomas [43], and several alternative regimens have been
23 tested using bevacizumab as monotherapy or combined with other cytotoxic agents, i.e.,
24 irinotecan, temozolomide or nitrosourea. A trial of the EORTC focusing on the sequential
25 therapy of patients with first relapse of glioblastoma (EORTC 26101) using bevacizumab and
26 CCNU in several combinations is enrolling patients at this time and additional controlled
27 studies involving proper histological, molecular and imaging work-up are urgently needed to
28 identify those patients that are most likely to benefit.

29
30 In addition to the use of bevacizumab in relapse, two first-line phase III trials have been
31 initiated that have shown early promising results of a significant increase of PFS in
32 glioblastoma [26]. The difference in OS was not significant at the time of presentation,
33 suggesting that bevacizumab may only prolong the clinically relevant first phase of the
34 disease until first progression. As such, an improved understanding of the side-effects of

targeted agents appears necessary. Antiangiogenic therapy has been shown to increase the invasive properties of glioma cells. Early in vitro data [73] have recently been challenged by observations from human high-grade glioma trials using bevacizumab, where an increased FLAIR-enhancement suggesting increased invasion has been observed using magnetic resonance imaging (MRI) [3, 102]. However, other investigators could not reproduce these results [147]. These multidisciplinary results from both basic research as well as clinical studies raise the question if a combined use of anti-angiogenic and anti-invasive drugs may be advantageous and warrant careful evaluation of clinical and imaging response as well as effects on tumor progression and overall survival.

Argument #3: Basic research is needed to drive translational research

The development of novel anticancer therapies is a major goal in neurooncology, yet progress in this direction is still moderate. Since many substances fail in controlled clinical trials, the costs for the substances that reach market approval are tremendously high. Thus, less fragmented and instead more streamlined and cost-effective research approaches are needed. Translational research is a promising way to bridge basic and clinical research. There is a growing awareness of the fact that basic scientists on the one hand should provide input into the development of clinical trials and that pre-clinical research projects would benefit from the input of clinicians. Molecular aspects have to be better incorporated into clinical studies and clinical demands have to be considered for defining relevant basic research projects. A translational research pipeline that turns basic scientific discoveries into clinical applications is a long and multistep process that requires a committed dialogue between experts from multiple disciplines. It will also be enriched by qualified individuals with medical and laboratory-based knowledge (so-called physician scientists). In our conceptional framework academically-based brain tumor centers that harbor both clinical and basic research disciplines are therefore ideally suited for addressing this task (Fig. 1).

#3a: Deeper insights into tumor biology are needed to identify novel promising targets of clinical use

Innovative treatment approaches necessarily require insights into the molecular basis of the disease. Over the past twenty years, tremendous progress has been made in unveiling the

different pathophysiological events contributing to gliomagenesis and glioma progression. Indeed, “glioma” is a heterogeneous group of diseases, and the subsequent hope is that the different molecular events could be targeted by distinct treatment approaches. Processes may be targeted, for example angiogenesis or tumor cell proliferation. Experimental data from *in situ* analyses and microdissected glioma cell populations from different tumor regions suggest, for example, that infiltrating glioma cells contain unique molecular profiles [33, 84] and some of these differentially activated molecules and pathways could serve as targets for therapies aiming at reduction of the infiltrative nature of the disease: among others, the dysregulation of EGFR and integrin signaling pathways could affect the tumor infiltration zone [74, 95, 116].

Recent studies have raised the possibility that tumor-initiating cells such as cancer stem cells may be the most relevant targets for successful therapies [9, 12, 141]. The hypoxic niche is appreciated as a major relevant local factor for the growth and propagation of glioma stem cells [128]. In this regard, targeting the vascular components of the niche can lead to eradication of brain tumor initiating cells (BTICs) [42, 55]. Interestingly in this context, the expression of C/EBPbeta (one of the master regulators of the mesenchymal expression signature; see below) is closely associated with areas of necrosis, i.e., areas of intratumoral hypoxia [28]. Thus, targeting tumor cells with a hypoxia-tag may be particularly promising in eradicating those cell populations that sustain tumor growth and regrowth. Nevertheless, the definition and identification of tumor-initiating cell populations has to be refined to enable potential novel stem-cell directed therapeutic approaches.

While the above studies suggest the possibility of reasonable targets, this is only the first part in a long experimental pipeline for the development of successful clinical therapies. Experimental findings derived from cell culture and animal models have to be verified for their relevance to the human *in vivo* situation. Novel potential target molecules should be loaded with clinical prognostic and predictive information. As such, close interfaces between basic scientists and clinicians are essential to drive the development of these basic research insights into practical clinical applications and will require a multidisciplinary and translational research environment.

#3b: Molecular alterations have to be put into a meaningful context to extract those molecular changes that really matter

While many individual molecules could be targeted, approaches directed against single molecules have failed to date (see below, #4a). One reason for such failure may be that the tumor does not depend on the specific targeted molecular alteration, given the complexity of intracellular signaling relationships. Multiple alternative upstream alterations may lead to the dysregulation of identical downstream signaling intermediates in pathways [113, 116]. The situation becomes even more complex due to intratumoral heterogeneity and because multiple levels of molecular regulation affect one another (Fig. 2). In addition to genomic alterations (such as mutations or gene amplification), RNA and protein alterations contribute to a molecular make-up of the tumor. Epigenetic regulation superimposes an additional regulatory layer, with not only gene methylation and histone modifications but also miRNAs regulating complex networks of cancer genes. These signaling relationships have to be kept in mind when designing targeted therapeutic approaches and basic research can therefore best drive translational research by *putting genes into context*.

In 2008, The Cancer Genome Atlas (TCGA) reported an integrative analysis of DNA copy number, gene expression and DNA methylation profiling in a collection of 206 human glioblastomas [22]. This study confirmed the multitude of molecular aberrations that had been previously identified by individual researchers but also highlighted three signaling pathways of major importance in the broad majority of these tumors: CDK/cyclin/CDK inhibitor/pRB, p53, and RTK/RAS/PI3K (Fig. 3). A second approach substantiated these major molecular pathways defining glioblastomas [98]. These common pathways may serve to provide central targets to target the disease efficiently.

As mentioned above, global molecular approaches may also identify novel prognostic subclasses of high-grade astrocytomas: proneural, proliferative and mesenchymal expression patterns [11, 28, 75, 99, 140]. While tumors from the proneural subclass are highly enriched for neuronal lineage markers and exhibit better survival, proliferative and mesenchymal tumor subclasses are enriched for neuronal stem cell markers and display shorter survival. Upon recurrence, a frequent shift in expression patterns towards the mesenchymal subclass has been observed. Of note, two transcription factors (C/EBPbeta and STAT3) have been suggested as master regulators that could control the transition into a prognostically unfavorable gene expression profile [23]. Experimentally, the ectopic co-expression of C/EBPbeta and STAT3

1 reprogrammed neural stem cells along the aberrant mesenchymal lineage, while elimination
2 of the two factors in glioma cells resulted in a loss of the mesenchymal signature and a
3 reduction of tumour aggressiveness. Given that a hierarchy with a concerted regulation of
4 multiple molecules exists and that a shift of whole expression patterns can be induced by
5 single molecules, C/EBPbeta and STAT3 could be priority targets for therapeutic
6 intervention.

7
8 In addition, meaningful molecular signatures may not only be restricted to the transcriptional
9 level. For example, the TCGA highlighted a distinct subset of samples that had concerted
10 hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island
11 methylator phenotype (G-CIMP) [92]. This hypermethylation signature overlapped with the
12 proneuronal expression signature described above, and was more prevalent among lower-
13 grade gliomas and associated with a significantly improved outcome. More recently,
14 additional subgroups of glioblastoma with distinct global methylation patterns have been
15 suggested defined by H3F3A mutations affecting two critical amino acids (K27 and G34) of
16 histone H3.3 [132], and others have subgrouped glioblastomas according to miRNA
17 expression profiles [67, 105] or histone modification patterns [80].

18
19 These findings indicate that biological knowledge of glioma biology is becoming increasingly
20 complex and that advanced bioinformatic methods are needed to allow cross-platform
21 correlations for extracting those molecular changes that are most meaningful in a clinical
22 context. Basic and translational scientists as well as bioinformaticians need to be included in
23 multidisciplinary research-orientated brain tumor teams. While not directly involved in
24 clinical patient care, they can well contribute innovative impulses by identifying promising
25 and relevant molecular targets for further clinical exploration.

26 27 28 29 **Argument #4: Translational research is needed to drive clinical research**

30
31 “From bench to bedside” is a goal occasionally envisaged in ambitious research grant
32 proposals. As obvious from the examples provided above, basic tumor-biology orientated
33 research approaches may be distant from clinical applications and benefit from the input of
34 clinically orientated researchers in order to be catalyzed into practical patient care. On the

other hand, since basic research is necessarily more speculative and hypothesis-driven it may therefore - in the long run - lead to more fundamental breakthroughs and more radical paradigm shifts in practice than would clinical research alone. As such clinical research depends on basic research input to ask the most innovative questions, leave well-trodden trails and thereby accelerate therapeutic advancements.

#4a: Clinical studies are needed that are based on attractive molecular targets derived from basic research approaches

Translational research requires the transfer of basic scientific findings into clinical applications. Earlier in this review we introduced bevacizumab as the currently most advanced targeting agent that supplements therapeutic options in glioma care. In addition, other promising molecular targets have been or are currently being tested in early clinical trials. The most important of these are summarized in the following section.

- *Antiangiogenic agents other than bevacizumab*

In addition to bevacizumab, several small molecule tyrosine kinase inhibitors as sunitinib [91, 97], sorafenib [34, 90], cediranib [7, 8], pazopanib [60], vatalanib [14, 107] and vandetanib [36, 70] have anti-angiogenic properties (Fig. 3). The molecular mechanism of these agents is similar in that each binds angiogenesis-relevant receptor tyrosine kinases or intracellular signaling molecules and therefore inhibits angiogenic signaling pathways. Inhibiting multiple targets at once may overcome the redundancy of intracellular signaling pathways. Suprisingly, none of the mentioned antiangiogenic agents except bevacizumab has been effective in clinical studies. Cediranib showed significant efficacy in an animal model and promising results in an early phase I/II clinical trial and therefore entered phase III in newly diagnosed glioblastoma, based on a strong drug development pathway of the respective company [6, 8, 61]. However, it then failed, leading to the assumption that it might be more promising to inhibit the ligand rather than the receptor or signaling cascade of antiangiogenic pathways.

- *Targeting the integrin cell adhesion receptor family*

The alphaV-beta3 and alphaV-beta5 integrin receptors are expressed in glioma and tumor endothelial cells [24], contribute to tumor angiogenesis and migration, and may thus constitute promising targets for specific approaches. Cilengitide is a selective

inhibitor of integrins on endothelial cells with a predominant antiangiogenic effect, but has a bimodal biological effect since it also shows anti-invasive properties on tumor cells [124]. The inhibitor was investigated in several clinical protocols [87, 109, 110, 111, 130] and a promising median PFS of 8 months and 12- and 24-month overall survival rates of 68% and 35% have been reported in first-line therapy [130], especially for patients whose tumors have a methylated *MGMT* promoter. These clinical data led to the initiation of a large registration trial for patients in the primary therapy of glioblastoma with *MGMT* promoter methylation (CENTRIC; [133]) and a smaller phase II trial for patients whose tumors have non-methylated *MGMT*. Results were recently communicated in a press release by Merck; there was no benefit for the combination of radiochemotherapy with cilengitide in comparison to radiochemotherapy alone.

- *Tyrosine kinase receptor inhibition*

EGFR is amplified or overexpressed in its truncated form (EGFRvIII) in many glioblastomas, inducing excess kinase activity [115]. However, EGFR kinase inhibitors such as gefitinib, erlotinib and lapatinib have been unsuccessful in clinical trials [29, 103, 152]. Successful treatment has been claimed for some patients with coexpression of EGFRvIII and PTEN [89], but this has not been confirmed in subsequent studies. Recently, an investigational immunotherapeutic vaccine that targets the tumor-specific EGFRvIII has been developed and is currently being investigated in the international phase II and III ACT IV trial [31, 32].

PDGFR is another attractive target for the treatment of high-grade gliomas given the presence of *PDGFR* amplification/overexpression in many of these tumors [115]. The small molecule inhibitor imatinib mesylate was developed in the 1990s and is a ground breaking targeted agent that shows an over 90% response rate in chronic myeloid leukemia [37, 38]. Following the publication of first results from these trials, imatinib was investigated in a number of solid tumors. However, after promising early results [108], a phase III registration trial in high-grade gliomas was negative [106], illustrating that tumors that do not depend on a single driver oncogene will likely not respond to such therapeutic approaches.

- *Other targeted approaches*

Inhibitors of protein kinase C β [15, 16, 69, 104, 150], PI3K/Akt/mTor inhibitors [25, 44, 123] and inhibitors of other receptor kinase or intracellular targets (e.g. notch, SHH,

1 histone deacetylase) have been investigated in phase II or early phase I trials and have
2 failed, despite promising laboratory and animal data. In terms of immunomodulatory
3 therapies, TGF- β 2 targeted antibodies, antisense oligonucleotides or small molecule
4 inhibitors are the most advanced in clinical application [48, 49, 50, 126, 127], but their
5 efficacy remains unclear at this time.

6
7 Most investigated targeted agents, therefore, have been unsuccessful to date in clinical phase
8 II and III trials. This raises the question of why these biologically compelling molecules did
9 not turn out to be clinically effective. The most ready explanation for such failure is that
10 agents targeting a single molecule may not be sufficient to tackle the highly complex
11 molecular oncogenic backbone of glioblastomas. Instead, multitargeted approaches may
12 constitute an attractive and improved option and, as a result, first attempts in this direction
13 have been made by using multi-target inhibitors as sorafenib [34, 90], cediranib [13] and
14 sunitinib (against VEGFR1-3, PDGFR-a/b, FLT-3, c-KIT and RET) [91, 97] or combinations
15 of cilengitide plus temozolomide [130]), EGFR-targeted vaccination and temozolomide [53],
16 or bevacizumab plus irinotecan (Genentech trial; [43]).

17
18
19 ***#4b: Mechanisms of therapy failure and resistance have to be understood to improve***
20 ***therapeutic regimens***

21
22 Most glioblastoma patients receive intensive neurooncological postsurgical care and are
23 included into controlled clinical trials or are treated with standard radiochemotherapy using
24 concomitant and adjuvant temozolomide [131]. Thus, the issue of chemotherapy resistance or
25 failure becomes more important in terms of improving therapeutic regimens. Major
26 preexisting tumor-intrinsic reasons for low efficacy of chemo- and targeted therapy against
27 glioblastoma are poor blood-brain barrier penetration of cytostatic agents (especially in the
28 therapeutically relevant periphery of the tumor) [46], expression of drug efflux pumps
29 (multidrug resistance genes) [30, 63, 79], and the expression of resistance-associated proteins
30 such as MGMT [51]. However, because of genetic instability and clonal selection, tumor cells
31 may also develop molecular escape mechanisms under therapy that counteract the beneficial
32 effects of alkylating chemotherapeutic agents.

1 In a recent study by the German Glioma Network, pairs of primary and recurrent tumors from
2 64 glioblastoma patients treated with radiotherapy and TMZ were investigated, revealing
3 significantly lower expression levels of the mismatch repair genes *MSH2*, *MSH6* and *PMS2*
4 but no relevant changes in *MGMT* promoter hypermethylation [134]. Indeed, *MSH6* in this
5 context appears to be a relevant player. A large-scale sequencing screen of the functional
6 domains of 518 protein kinases identified inactivating somatic mutations of the mismatch
7 repair gene *MSH6* in two gliomas that had recurred after treatment with alkylating agents [58]
8 and sequencing of *MSH6* in 46 clinically well-characterized glioblastomas revealed that the
9 frequency of *MSH6* mutations was significantly increased in recurrent glioblastomas [17].
10 These data suggest that *MSH6* deficiency (and maybe also the deficiency of other mismatch
11 repair genes) may contribute to recurrences during maintenance treatment and that patients
12 who initially responded to a frontline therapy may evolve treatment resistance by developing
13 a hypermutator phenotype [153]. Further *in vitro* data indicated that through exposure of an
14 *MSH6* wild-type glioblastoma line to temozolomide resistant clones evolved with one of them
15 harboring an *MSH6* mutation [22]. Also, knockdown of *MSH6* in the U251 glioblastoma cell
16 line increased resistance to temozolomide cytotoxicity and its reconstitution restored
17 cytotoxicity in *MSH6*-null glioma cells. It is hoped that better understanding of the biological
18 mechanisms by which tumor cells escape the response to chemotherapy may be utilized to
19 develop novel strategies to overcome or at least minimize chemotherapy resistance; for
20 example, with respect to *MSH6*, a possible approach would be an upfront combination of
21 alkylating agents with selective agents targeting mismatch-repair-deficient cells.

22
23 Further studies are needed to extend these observations, including to the epigenetic level. For
24 example, in temozolomide resistant glioma cells, LINE-1 methylation, an indicator of global
25 DNA-methylation and a positive prognostic factor in gliomas, is reduced [45, 94]. This could
26 suggest that a lower global DNA methylation impairs DNA stability and activates novel
27 chemotherapy resistance. Based on the knowledge about molecular markers for early response
28 and resistance, adaptive clinical trials could be designed that would better overcome the
29 therapeutic resistance of gliomas.

Conclusions

The approaches described above, within or outside clinical trials, can only be coordinated at dedicated brain tumor centers. A number of such centers have been founded within the last decades, starting from the US and now reaching Europe and Asia. Such centers typically include departments of neurosurgery, radiation oncology, neurology and medical oncology, and specialized diagnostic units for neuropathology and neuroradiology. Our experiences working in such environments suggest that the individual patient case must be coordinated prospectively (including discussions on diagnostics and treatment planning) to meet the goals of quick decision making and structured, tailored treatment. We would argue further that a strong agenda combining translational development of new treatment approaches with the performance of clinical trials is best suited to serve patients both within clinical trials and also on an individual basis.

Equally important is a close connection of brain tumor centers with local institutions and community-based physicians. Such connectivity is essential to make local treatment possible, especially with regard to supportive treatments and management of complications. Local medical centers in this regard assume an important role in our conceptional framework of multidisciplinary and multiinstitutional brain tumor management (Fig. 1). Expertise can be brought to local centers by use of electronically connected consults and tumor boards. In such cooperative networks, local medical centers would be able to incorporate expertise from highly specialized disciplines, such as neuropathology and neuroradiology that might not be locally available. Bringing cutting edge diagnostics and treatment "close to home" is an optimal patient-oriented solution that can be reached when central and local strengths synergize.

References

1. Ahluwalia MS (2011) American Society of Clinical Oncology 2011 CNS tumors update. *Expert Rev Anticancer Ther* 11:1495-1497
2. Alexiou GA, Tsiouris S, Voulgaris S, Kyritsis AP and Fotopoulos AD (2012) Glioblastoma multiforme imaging: the role of nuclear medicine. *Curr Radiopharm* 5:308-313
3. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T and Pope WB (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. *J Neurooncol* 88:339-347
4. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 116:597-602
5. Bar EE, Lin A, Tihan T, Burger PC and Eberhart CG (2008) Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. *J Neuropathol Exp Neurol* 67:878-887
6. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY and Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. *J Clin Oncol* 28:2817-2823
7. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY and Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. *J Clin Oncol* 28:2817-2823
8. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY and Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell* 11:83-95
9. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. *Cancer Res* 67:4010-4015
10. Bettstetter M, Dechant S, Ruemmele P, Vogel C, Kurz K, Morak M, Keller G, Holinski-Feder E, Hofstaedter F and Dietmaier W (2008) MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples. *Lab Invest* 88:1367-1375
11. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, Lang FF, Rao G, Copray S, Vaillant BD and Aldape KD (2011) The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. *Genes Dev* 25:2594-2609
12. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J and Terzis AJ (2005) Opinion: the origin of the cancer stem cell: current controversies and new insights. *Nat Rev Cancer* 5:899-904
13. Bradley DP, Tessier JJ, Lacey T, Scott M, Jurgensmeier JM, Odedra R, Mills J, Kilburn L and Wedge SR (2009) Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. *Magn Reson Imaging* 27:377-384
14. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM and van den Bent MJ (2010) EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. *Eur J Cancer* 46:348-354

- 1 15. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L,
2 Nicol SJ, Thornton DE and Prados MD (2010) Enzastaurin plus temozolomide with radiation
3 therapy in glioblastoma multiforme: a phase I study. *Neuro Oncol* 12:608-613
- 4 16. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni
5 R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ,
6 Thornton DE and Prados MD (2011) Phase II and pharmacogenomics study of enzastaurin plus
7 temozolomide during and following radiation therapy in patients with newly diagnosed
8 glioblastoma multiforme and gliosarcoma. *Neuro Oncol* 13:1331-1338
- 9 17. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA,
10 Stratton MR, Curry WT, Iafrate AJ and Louis DN (2007) Loss of the mismatch repair protein
11 MSH6 in human glioblastomas is associated with tumor progression during temozolomide
12 treatment. *Clin Cancer Res* 13:2038-2045
- 13 18. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K,
14 Souhami L, Laperriere N, Mehta M and Curran W (2006) Phase III trial of chemotherapy plus
15 radiotherapy compared with radiotherapy alone for pure and mixed anaplastic
16 oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. *J Clin Oncol*
17 24:2707-2714
- 18 19. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC,
19 Macdonald DR, Ino Y, Ramsay DA and Louis DN (1998) Specific genetic predictors of
20 chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. *J Natl*
21 *Cancer Inst* 90:1473-1479
- 22 20. Cairncross JG, Wang M, Shaw EG, Jenkins RB, Scheithauer BW, Brachman D, Buckner JC, Fink KL,
23 Souhami L, Laperriere N, Curran WJ and Mehta MP (2012) Chemotherapy plus radiotherapy (CT-
24 RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the
25 RTOG 9402 phase III study. *J Clin Oncol* 30:ASCO MEETING ABSTRACTS (suppl; abstr 2008b)
- 26 21. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN and Nutt CL (2010) Mutant IDH1-
27 specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. *Acta*
28 *Neuropathol* 119:509-511
- 29 22. CancerGenomeAtlasResearchNetwork (2008) Comprehensive genomic characterization defines
30 human glioblastoma genes and core pathways. *Nature* 455:1061-1068
- 31 23. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F,
32 Colman H, Lasorella A, Aldape K, Califano A and Iavarone A (2010) The transcriptional network
33 for mesenchymal transformation of brain tumours. *Nature* 463:318-325
- 34 24. Chamberlain MC, Cloughesy T, Reardon DA and Wen PY (2012) A novel treatment for
35 glioblastoma: integrin inhibition. *Expert review of neurotherapeutics* 12:421-435
- 36 25. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L,
37 Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancy J and Prados MD (2005) Phase II study of
38 CCI-779 in patients with recurrent glioblastoma multiforme. *Invest New Drugs* 23:357-361
- 39 26. Chinot OL, de La Motte Rouge T, Moore N, Zeaier A, Das A, Phillips H, Modrusan Z and
40 Cloughesy T (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy
41 in newly diagnosed glioblastoma multiforme. *Adv Ther* 28:334-340
- 42 27. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W and Weiler M
43 (2012) Prognostic value of three different methods of MGMT promoter methylation analysis in a
44 prospective trial on newly diagnosed glioblastoma. *PLoS One* 7:e33449
- 45 28. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, Kurc T, Van Meir EG, Saltz JH,
46 Moreno CS and Brat DJ (2012) The tumor microenvironment strongly impacts master
47 transcriptional regulators and gene expression class of glioblastoma. *Am J Pathol* 180:2108-2119
- 48 29. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H,
49 Puduvalli VK, Levin V and Yung WK (2008) Phase II study of carboplatin and erlotinib (Tarceva,
50 OSI-774) in patients with recurrent glioblastoma. *J Neurooncol* 90:89-97
- 51 30. Decleves X, Amiel A, Delattre JY and Scherrmann JM (2006) Role of ABC transporters in the
52 chemoresistance of human gliomas. *Curr Cancer Drug Targets* 6:433-445

- 1 31. Del Vecchio CA, Li G and Wong AJ (2012) Targeting EGF receptor variant III: tumor-specific
2 peptide vaccination for malignant gliomas. *Expert Rev Vaccines* 11:133-144
- 3 32. Del Vecchio CA and Wong AJ (2010) Rindopepimut, a 14-mer injectable peptide vaccine against
4 EGFRvIII for the potential treatment of glioblastoma multiforme. *Curr Opin Mol Ther* 12:741-754
- 5 33. Delic S, Lottmann N, Jetschke K, Reifenberger G and Riemenschneider MJ (2012) Identification
6 and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated
7 candidate genes. *Neuropathol Appl Neurobiol* 38:201-212
- 8 34. Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR,
9 Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K and Dicker
10 AP (2012) A Phase I Study of the Combination of Sorafenib With Temozolomide and Radiation
11 Therapy for the Treatment of Primary and Recurrent High-Grade Gliomas. *Int J Radiat Oncol Biol*
12 *Phys* 85:321-8
- 13 35. Dhermain FG, Hau P, Lanfermann H, Jacobs AH and van den Bent MJ (2010) Advanced MRI and
14 PET imaging for assessment of treatment response in patients with gliomas. *Lancet Neurol*
15 9:906-920
- 16 36. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C,
17 Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE and Wen PY
18 (2010) Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed
19 glioblastoma. *Int J Radiat Oncol Biol Phys* 78:85-90
- 20 37. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R and Talpaz M
21 (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic
22 myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl*
23 *J Med* 344:1038-1042
- 24 38. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H,
25 Capdeville R, Ohno-Jones S and Sawyers CL (2001) Efficacy and safety of a specific inhibitor of
26 the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med* 344:1031-1037
- 27 39. Einstein DB, Wessels B, Bangert B, Fu P, Nelson AD, Cohen M, Sagar S, Lewin J, Sloan A, Zheng Y,
28 Williams J, Colussi V, Vinkler R and Maciunas R (2012) Phase II trial of radiosurgery to magnetic
29 resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma
30 multiforme. *Int J Radiat Oncol Biol Phys* 84:668-674
- 31 40. Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, Stoffels G and Stummer W (2011)
32 Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET,
33 and intraoperative, ALA-derived tissue fluorescence. *Clin Neurol Neurosurg* 113:541-547
- 34 41. Felsberg J, Erkwow A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler
35 OD and Reifenberger G (2004) Oligodendroglial tumors: refinement of candidate regions on
36 chromosome arm 1p and correlation of 1p/19q status with survival. *Brain Pathol* 14:121-130
- 37 42. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ and Kerbel RS (2007) Anticancer therapies combining
38 antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma
39 xenograft tumors. *Cancer Res* 67:3560-3564
- 40 43. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N,
41 Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T (2009) Bevacizumab
42 alone and in combination with irinotecan in recurrent glioblastoma. *J Clin Oncol* 27:4733-4740
- 43 44. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil
44 SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M and Walsh DJ (2005) Phase II
45 trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer
46 Treatment Group Study. *J Clin Oncol* 23:5294-5304
- 47 45. Hoppold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G and Weller M
48 (2012) Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma
49 cells. *J Neurochem* [Epub ahead of print]
- 50 46. Haroun RI and Brem H (2000) Local drug delivery. *Curr Opin Oncol* 12:187-193
- 51 47. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G,
52 Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M and von Deimling A (2010)

- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathol* 120:707-718
48. Hau P, Jachimczak P and Bogdahn U (2009) Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. *Expert Rev Anticancer Ther* 9:1663-1674
 49. Hau P, Jachimczak P, Schlaier J and Bogdahn U (2011) TGF-beta2 signaling in high-grade gliomas. *Curr Pharm Biotechnol* 12:2150-2157
 50. Hau P, Jachimczak P, Schlingensiepen R, Stauder G, Bogdahn U, Schlingensiepen K and al. e (2007) Inhibition of TGF-beta2 with AP 12009 in recurrent malignant glioma: From preclinical to Phase I/II studies. *Oligonucleotides* 17:201-12.
 51. Hau P, Stupp R and Hegi ME (2007) MGMT methylation status: the advent of stratified therapy in glioblastoma? *Disease markers* 23:97-104
 52. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 352:997-1003
 53. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD and Sampson JH (2008) Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. *Neuro Oncol* 10:98-103
 54. Hewitt RE (2011) Biobanking: the foundation of personalized medicine. *Curr Opin Oncol* 23:112-119
 55. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J and Gurney A (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. *Cell Stem Cell* 5:168-177
 56. Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA and Diaz LA, Jr. (2012) Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. *J Neurooncol* 110:279-285
 57. Hummel R, Maurer J and Haier J (2011) MicroRNAs in brain tumors : a new diagnostic and therapeutic perspective? *Mol Neurobiol* 44:223-234
 58. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA and Wooster R (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. *Cancer Res* 66:3987-3991
 59. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT and Collins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro Oncol* 11:341-347
 60. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD and Fine HA (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). *Neuro Oncol* 12:855-861
 61. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG and Batchelor TT (2007) Angiogenesis in brain tumours. *Nat Rev Neurosci* 8:610-622
 62. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG and Batchelor TT (2007) Angiogenesis in brain tumours. *Nature Reviews Neuroscience* 8:610-622
 63. Jennings MT and Iyengar S (2001) The molecular genetics of therapeutic resistance in malignant astrocytomas. *Am J Pharmacogenomics* 1:93-99

- 1 64. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K and Collins VP (2008)
2 Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of
3 pilocytic astrocytomas. *Cancer Res* 68:8673-8677
- 4 65. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K and Collins VP (2009) Oncogenic RAF1
5 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating
6 the MAPK pathway in pilocytic astrocytoma. *Oncogene* 28:2119-2123
- 7 66. Khasraw M, Simeonovic M and Grommes C (2012) Bevacizumab for the treatment of high-grade
8 glioma. *Expert Opin Biol Ther* 12:1101-1111
- 9 67. Kim TM, Huang W, Park R, Park PJ and Johnson MD (2011) A developmental taxonomy of
10 glioblastoma defined and maintained by MicroRNAs. *Cancer Res* 71:3387-3399
- 11 68. Kleihues P and Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical
12 diagnosis. *Neuro Oncol* 1:44-51
- 13 69. Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D and Fine HA (2010) A
14 phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. *Neuro Oncol* 12:181-
15 189
- 16 70. Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J and Fine HA (2012) A phase I/II trial of
17 vandetanib for patients with recurrent malignant glioma. *Neuro Oncol* 14:1519-1526
- 18 71. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F,
19 Giannini C, Mokhtari K, Mork SJ, Paetau A, Reifenberger G and van den Bent MJ (2007) Panel
20 review of anaplastic oligodendroglioma from European Organization For Research and
21 Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss,
22 and correlations with outcome. *J Neuropathol Exp Neurol* 66:545-551
- 23 72. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge
24 J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P,
25 Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB,
26 Liao LM, Elashoff RM, Cloughesy TF, Yong WH and Lai A (2013) Combined analysis of O6-
27 methylguanine-DNA methyltransferase protein expression and promoter methylation provides
28 optimized prognostication of glioblastoma outcome. *Neuro Oncol* 15:370-381
- 29 73. Lamszus K, Kunkel P and Westphal M (2003) Invasion as limitation to anti-angiogenic glioma
30 therapy. *Acta Neurochir Suppl* 88:169-177
- 31 74. Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G and Riemenschneider MJ (2011)
32 SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and
33 promotes glioma cell invasion through STAT3 and FAK activation. *Acta Neuropathol* 122:241-251
- 34 75. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U,
35 Wischhusen J, Spang R, Storch A and Beier CP (2010) Transcriptional profiles of CD133+ and
36 CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. *Cancer Res*
37 70:2030-2040
- 38 76. Louis DN (2006) Molecular pathology of malignant gliomas. *Annu Rev Pathol* 1:97-117
- 39 77. Louis DN (2012) The next step in brain tumor classification: "Let us now praise famous men"... or
40 molecules? *Acta Neuropathol* 124:761-762
- 41 78. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK and (eds.) (2007) WHO classification of tumours
42 of the central nervous system. 4th edn. IARC Press, Lyon
- 43 79. Lu C and Shervington A (2008) Chemoresistance in gliomas. *Molecular and cellular biochemistry*
44 312:71-80
- 45 80. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa
46 ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK and
47 Thompson CB (2012) IDH mutation impairs histone demethylation and results in a block to cell
48 differentiation. *Nature* 483:474-478
- 49 81. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN,
50 Schramm J, Wiestler OD and von Deimling A (1997) Molecular genetic evidence for subtypes of
51 oligoastrocytomas. *J Neuropathol Exp Neurol* 56:1098-1104

- 1 82. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B,
2 Lhermitte B, Hegi ME, Rosell J and Henriksson R (2012) Temozolomide versus standard 6-week
3 radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with
4 glioblastoma: the Nordic randomised, phase 3 trial. *Lancet Oncol* 13:916-926
- 5 83. Malzkorn B, Wolter M, Riemenschneider MJ and Reifenberger G (2011) Unraveling the glioma
6 epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. *Brain*
7 *Pathol* 21:619-632
- 8 84. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW,
9 Watts G, Trent JM, Wei JS, Giese A and Berens ME (2001) Glioma cell motility is associated with
10 reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. *J*
11 *Neurooncol* 53:161-176
- 12 85. Masui K, Cloughesy TF and Mischel PS (2012) Review: molecular pathology in adult high-grade
13 gliomas: from molecular diagnostics to target therapies. *Neuropathol Appl Neurobiol* 38:271-
14 291
- 15 86. Matsusue E, Fink JR, Rockhill JK, Ogawa T and Maravilla KR (2010) Distinction between glioma
16 progression and post-radiation change by combined physiologic MR imaging. *Neuroradiology*
17 52:297-306
- 18 87. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D,
19 Neuteboom B and Goodman SL (2009) Radiation sensitization of glioblastoma by cilengitide has
20 unanticipated schedule-dependency. *Int J Cancer* 124:2719-2727
- 21 88. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller
22 M, Wiestler OD, Louis DN and von Deimling A (2002) Genetic signature of oligoastrocytomas
23 correlates with tumor location and denotes distinct molecular subsets. *Am J Pathol* 161:313-319
- 24 89. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W,
25 Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC,
26 Domany E, Delorenzi M, Stupp R and Hegi ME (2008) Stem cell-related "self-renewal" signature
27 and high epidermal growth factor receptor expression associated with resistance to concomitant
28 chemoradiotherapy in glioblastoma. *J Clin Oncol* 26:3015-3024
- 29 90. Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X,
30 Wright J, Gujar S and Grossman SA (2011) Phase I trial of sorafenib in patients with recurrent or
31 progressive malignant glioma. *Neuro Oncol* 13:1324-1330
- 32 91. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen
33 N, Michotte A and De Greve J (2011) Phase II study of sunitinib malate in patients with recurrent
34 high-grade glioma. *J Neurooncol* 103:491-501
- 35 92. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloso CE,
36 Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson
37 RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB,
38 Laird PW and Aldape K (2010) Identification of a CpG Island Methylator Phenotype that Defines
39 a Distinct Subgroup of Glioma. *Cancer Cell* 17:510-522
- 40 93. Ohgaki H and Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. *Am J*
41 *Pathol* 170:1445-1453
- 42 94. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui
43 T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M and Wakabayashi T (2011) The global DNA
44 methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and
45 is a better prognostic factor for glioma. *PLoS One* 6:e23332
- 46 95. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL and Louis DN (2003) Selection pressures
47 of TP53 mutation and microenvironmental location influence epidermal growth factor receptor
48 gene amplification in human glioblastomas. *Cancer Res* 63:413-416
- 49 96. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris
50 JM, Hoover JM, Hu LS, Sarkaria JN and Brinkmann DH (2013) Biopsy validation of 18F-DOPA PET
51 and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation:
52 results of a prospective pilot study. *Neuro Oncol* 2013 Mar 3 [Epub ahead of print]

97. Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P and Chamberlain M (2012) A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. *J Neurooncol* 110:111-118
98. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE and Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. *Science* 321:1807-1812
99. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 9:157-173
100. Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, Galldiks N, Coenen HH, Kaiser HJ, Langen KJ and Eble MJ (2012) Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. *Strahlenther Onkol* 188:334-339
101. Plate KH, Scholz A and Dumont DJ (2012) Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. *Acta Neuropathol* 124:763-775
102. Pope WB, Lai A, Nghiemphu P, Mischel P and Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. *Neurology* 66:1258-1260
103. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D and Haas-Kogan DA (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. *J Clin Oncol* 27:579-584
104. Rampling R, Sanson M, Gorlia T, Lacombe D, Lai C, Gharib M, Taal W, Stoffregen C, Decker R and van den Bent MJ (2012) A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). *Neuro Oncol* 14:344-350
105. Rao SA, Santosh V and Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. *Mod Pathol* 23:1404-1417
106. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A and Nikolova Z (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. *Br J Cancer* 101:1995-2004
107. Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE, 2nd, Salvado AJ and Friedman HS (2009) Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. *Cancer* 115:2188-2198
108. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicieliński KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ and Friedman HS (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. *J Clin Oncol* 23:9359-9368
109. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M and Nabors LB (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. *J Clin Oncol* 26:5610-5617
110. Reardon DA, Nabors LB, Stupp R and Mikkelsen T (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. *Expert Opin Investig Drugs* 17:1225-1235
111. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB and Stupp R (2011) Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. *Future oncology* 7:339-354

- 1 112. Reifenberger G and Louis DN (2003) Oligodendroglioma: toward molecular definitions in
2 diagnostic neuro-oncology. *J Neuropathol Exp Neurol* 62:111-126
- 3 113. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U and
4 Reifenberger G (1999) Amplification and overexpression of the MDM4 (MDMX) gene from 1q32
5 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. *Cancer Res*
6 59:6091-6096
- 7 114. Riemenschneider MJ, Hegi ME and Reifenberger G (2010) MGMT promoter methylation in
8 malignant gliomas. *Target Oncol* 5:161-165
- 9 115. Riemenschneider MJ, Jeuken JW, Wesseling P and Reifenberger G (2010) Molecular diagnostics
10 of gliomas: state of the art. *Acta Neuropathol* 120:567-584
- 11 116. Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G and Louis DN (2005) In situ analysis
12 of integrin and growth factor receptor signaling pathways in human glioblastomas suggests
13 overlapping relationships with focal adhesion kinase activation. *Am J Pathol* 167:1379-1387
- 14 117. Riemenschneider MJ and Reifenberger G (2009) Astrocytic tumors. *Recent Results Cancer Res*
15 171:3-24
- 16 118. Riemenschneider MJ and Reifenberger G (2009) Molecular neuropathology of gliomas. *Int J Mol*
17 *Sci* 10:184-212
- 18 119. Riemenschneider MJ and Reifenberger G (2010) Molecular neuropathology of low-grade gliomas
19 and its clinical impact. *Adv Tech Stand Neurosurg* 35:35-64
- 20 120. Riemenschneider MJ and Reifenberger G (2009) Novel insights into the pathogenesis of gliomas
21 based on large-scale molecular profiling approaches. *Curr Opin Neurol* 22:619-624
- 22 121. Sahm F, Capper D, Jeibmann A, Habel A, Paulus W, Troost D and von Deimling A (2012)
23 Addressing diffuse glioma as a systemic brain disease with single-cell analysis. *Arch Neurol*
24 69:523-526
- 25 122. Sana J, Hajdusch M, Michalek J, Vyzula R and Slaby O (2011) MicroRNAs and glioblastoma: roles
26 in core signalling pathways and potential clinical implications. *J Cell Mol Med* 15:1636-1644
- 27 123. Sarkaria JN, Galanis E, Wu W, Dietz AB, Kaufmann TJ, Gustafson MP, Brown PD, Uhm JH, Rao RD,
28 Doyle L, Giannini C, Jaeckle KA and Buckner JC (2010) Combination of temsirolimus (CCI-779)
29 with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is
30 associated with increased infectious risks. *Clin Cancer Res* 16:5573-5580
- 31 124. Scaringi C, Minniti G, Caporello P and Enrici RM (2012) Integrin inhibitor cilengitide for the
32 treatment of glioblastoma: a brief overview of current clinical results. *Anticancer research*
33 32:4213-4223
- 34 125. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling
35 P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W,
36 Reifenberger G and von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous
37 system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma,
38 ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathol* 121:397-405
- 39 126. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B and
40 Jachimczak P (2006) Targeted tumor therapy with the TGF-beta 2 antisense compound AP
41 12009. *Cytokine Growth Factor Rev* 17:129-139
- 42 127. Schlingensiepen R, Goldbrunner M, Szyrach MN, Stauder G, Jachimczak P, Bogdahn U,
43 Schulmeyer F, Hau P and Schlingensiepen KH (2005) Intracerebral and intrathecal infusion of the
44 TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and
45 primates: toxicology and safety. *Oligonucleotides* 15:94-104
- 46 128. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, Wolter M, Sommerlad D,
47 Henze AT, Nister M, Reifenberger G, Lundeberg J, Frisen J and Acker T (2010) A hypoxic niche
48 regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. *Brain* 133:983-995
- 49 129. Specenier P (2012) Bevacizumab in glioblastoma multiforme. *Expert Rev Anticancer Ther* 12:9-18
- 50 130. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG,
51 Ochsenein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A,
52 Hermisson M, Krueger S, Picard M and Weller M (2010) Phase I/IIa study of cilengitide and

- temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *J Clin Oncol* 28:2712-2718
131. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352:987-996
 132. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fruhwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Durken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bogner L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N and Pfister SM (2012) Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. *Cancer Cell* 22:425-437
 133. Tabatabai G, Tonn JC, Stupp R and Weller M (2011) The role of integrins in glioma biology and anti-glioma therapies. *Curr Pharm Des* 17:2402-2410
 134. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel MC, Hofmann S, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler OD, Hahn M, Lichter P, Reifenberger G and Radlwimmer B (2011) Molecular signatures classify astrocytic gliomas by IDH1 mutation status. *Int J Cancer* 128:1095-1103
 135. van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. *Acta Neuropathol* 120:297-304
 136. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D and Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. *J Clin Oncol* 24:2715-2722
 137. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T and Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. *Clin Cancer Res* 16:1597-1604
 138. van den Bent MJ, Hoang-Xuan K, Brandes AA, Kros JM, Kouwenhoven MCM, Taphoorn MJB, Delattre JY, Bernsen HJJB, Frenay M, Tijssen C, Grisold W, Sipos L, Enting RH, Dinjens WNM, French P, Vecht CJ, Allgeier A, Lacombe DA and Gorlia T (2012) Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). *J Clin Oncol* 30:ASCO MEETING ABSTRACTS (suppl; abstr 2)
 139. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytendewilligen L, Sillevius Smitt PA, Jenkins RB and Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. *Cancer* 97:1276-1284
 140. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM and Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 17:98-110
 141. Vescovi AL, Galli R and Reynolds BA (2006) Brain tumour stem cells. *Nat Rev Cancer* 6:425-436

142. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH and Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. *Clin Cancer Res* 13:1253-1259
143. Vultur A, Villanueva J and Herlyn M (2011) Targeting BRAF in advanced melanoma: a first step toward manageable disease. *Clin Cancer Res* 17:1658-1663
144. Walter F, la Fougere C, Belka C and Niyazi M (2012) Technical Issues of [(18)F]FET-PET Imaging for Radiation Therapy Planning in Malignant Glioma Patients - A Review. *Front Oncol* 2:130
145. Weber MA, Henze M, Tuitenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M, Giesel FL, Zoubaa S, Haberkorn U, Kauczor HU and Essig M (2010) Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? *Invest Radiol* 45:755-768
146. Weller M (2013) Assessing the MGMT status in glioblastoma: one step forward, two steps back? *Neuro Oncol* 15:253-254
147. Wick A, Dorner N, Schafer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M and Wick W (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. *Ann Neurol* 69:586-592
148. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A and Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. *J Clin Oncol* 27:5874-5880
149. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G and Weller M (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncology* 13:707-715
150. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE and Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. *J Clin Oncol* 28:1168-1174
151. Yang I and Aghi MK (2009) New advances that enable identification of glioblastoma recurrence. *Nat Rev Clin Oncol* 6:648-657
152. Ye F, Gao Q and Cai MJ (2010) Therapeutic targeting of EGFR in malignant gliomas. *Expert opinion on therapeutic targets* 14:303-316
153. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL and Louis DN (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. *Clin Cancer Res* 15:4622-4629

Tables and figure legends

Table 1. Molecular markers with diagnostic relevance.

<i>IDH1/2</i> mutation	<p><u>glioblastoma</u>: genetically either primary (<i>IDH</i> wildtype) or secondary (<i>IDH</i> mutated) glioblastoma</p> <p><u>high-grade glioma with overtly anaplastic histology lacking necrosis and not fulfilling all histological criteria for the diagnosis of glioblastoma</u>: lack of <i>IDH</i> mutations might point to a tumor that behaves like a glioblastoma</p> <p><u>gliosis versus glioma</u>: detection of invading tumor cells by the presence of a mutation increases the sensitivity of glioma diagnostics</p>
1p/19q deletion	<p><u>tumors with borderline oligodendroglial features</u>: detection of the 1p/19q codeletion may reflect a prognostically favorable oligodendroglioma diagnosis</p> <p><u>oligoastrocytoma</u>: may guide consideration as oligodendroglial (1p/19q deleted) or astrocytic in nature (1p/19q retained, <i>TP53</i> mutated).</p>
<i>BRAF</i> alterations	<p><u><i>BRAF-KIAA1549</i> fusion</u>: presence consistent with pilocytic astrocytoma rather than a diffusely infiltrative astrocytoma (particularly when tested in tandem with <i>IDH1</i> and <i>IDH1</i> not mutated).</p> <p><u><i>BRAF V600E</i> mutation</u>: for differentiation of pleomorphic xanthoastrocytoma, gangliogliomas and extra-cerebellar pilocytic astrocytomas (frequent <i>BRAF V600E</i> mutation) from diffusely infiltrating astrocytic gliomas (rare <i>BRAF V600E</i> mutation).</p>

Table 2. Ongoing or recently closed phase III clinical trials in adult patients with first line or relapsed glioblastoma, based on a search in ClinicalTrials.gov. All listed trials are recruiting or have not published results yet, except abstracts at scientific meetings. Only trials from major study groups and industry are listed. AvaGlio in abstract form has reported a PFS of 6.2 months for the standard arm and 10.6 months for the experimental arm ($p < 0.0001$).

Treatment	Short name	Disease	No. of Pat.	Endpoint	Mol. selection	Primary study group / company	Trial identifier
Bevacizumab + TMZ/RT vs. TMZ/RT	RTOG 0825	GBM, first-line	942	PFS, OS	no	RTOG	NCT00884741
Bevacizumab + TMZ/RT vs. TMZ/RT	AvaGlio	GBM, first-line	920	PFS, OS	no	Roche	NCT00943826
Cilengitide + TMZ/RT vs. TMZ/RT	CENTRIC	GBM, first-line	504	OS	yes (MGMT)	EORTC / Merck	NCT00689221
NovoTTF-100A + TMZ/RT vs. TMZ/RT	-	GBM, first-line	700	PFS	no	NovoCure	NCT00916409
Rindopepimut + GM-CSF vs. TMZ/RT	ACT IV	GBM, first-line	440	OS	yes (EGFRvIII)	Celldex	NCT01480479
RT (3 weeks) vs. TMZ/RT (3 weeks)	-	GBM, first-line (> 65 a)	560	OS	no	NCIC	NCT00482677

Figure 1. Conceptional framework of an optimized multidisciplinary brain tumor management as proposed in this review article. Affiliation of brain tumor patients to academically-based brain tumor centers guarantees state-of-the art treatment and enables access to innovate research-driven clinical approaches. Collaborative clinical networks convey expertise from brain tumor to local medical centers and allow for supportive treatment and management of complications “close to home” in a socially embedded environment.

Figure 2. Illustration of the layers of histological and molecular information that coexist within a patient’s diagnostic tumor sample. Typing and grading based on the histological classification represent the basis for the estimation of the tumors biological behavior. Histological diagnosis may be supplemented by molecular information on a multitude of genes, molecular markers or complex gene signatures. This molecular information is represented on different molecular levels (epigenetic, genomic, transcriptional) or in different areas of the tumor microstructure (e.g. tumor center vs. tumor border), but highly mutually interconnected: *IDH* mutations, e.g., might lead to global epigenetic changes and miRNAs regulate complex transcriptional networks. Nevertheless, the multitude of single molecular alterations converges into a manageable number of common signaling pathways. As such a context-dependent interpretation of individual molecular changes appears helpful for developing efficient targeted therapeutic strategies.

Figure 3. Candidate mechanisms and molecules for targeted therapies. A multitude of single molecular alterations converge into relatively common signaling pathways that are highly interconnected and that may be targeted by available agents. Features of tumor and endothelial cells have been combined in this figure and angiogenic pathways, which are clinically most relevant at this time, are overrepresented.